The prevalence of hypothyroidism, hypoadrenocorticism, and hypopituitarism was higher among the participants who received ipilimumab plus a PD-1 inhibitor; among participants who received ICI alone, the prevalence of any type of hypothyroidism was higher in participants treated with atezolizumab, nivolumab, and pembrolizumab in this order. This evidence concerns the gene PDCD1 and hypopituitarism.